Weekly Inhaled TB Treatment Could Replace Daily Pills

Tuberculosis patients might soon swap daily pills for a once-a-week inhaler, thanks to a breakthrough from University at Buffalo researchers.

The new treatment packages rifampin, a crucial TB drug, into tiny nanoparticles that patients breathe directly into their lungs. This matters because TB remains one of the world's deadliest infectious diseases, killing over a million people annually even though it's curable.

Current TB treatment requires patients to take multiple pills daily for six to nine months. The drugs often damage the liver and cause severe side effects, leading many patients to quit treatment early. When that happens, the disease returns stronger and becomes resistant to medication.

Jessica Reynolds, the study's senior author, explains the core problem with oral rifampin. Not enough medicine reaches the lungs where TB bacteria actually live, and the drug damages the liver as it passes through the body.

The inhaled nanoparticles solve both issues at once. They deliver medicine directly to lung immune cells called macrophages, where TB bacteria hide. The particles slowly release rifampin over days while boosting the immune system's ability to fight infection.

The research team tested their innovation in two different mouse models of TB infection. One represented typical lung infections, while the other mimicked severe human TB damage that's notoriously hard to treat.

The results exceeded expectations. A single inhaled dose kept high levels of rifampin in the lungs for up to a week, far longer than daily oral pills. This means patients could potentially take their medicine once weekly instead of every single day.

The Ripple Effect

The benefits extend far beyond tuberculosis treatment. Rifampin also fights other serious lung infections caused by non-tuberculous mycobacteria, which increasingly affect Americans with chronic lung disease.

There's another hidden advantage. When taken orally, rifampin interferes with other antibiotics doctors use to treat lung infections. By delivering the drug directly to the lungs, it bypasses the liver and avoids these dangerous drug interactions.

Patrick Kenney, a pediatrics professor on the research team, sees enormous potential. Doctors could finally use rifampin effectively for a broader range of lung infections without worrying about it weakening other medications.

The researchers conducted all their work in a certified Biosafety Level 3 facility under strict federal safety protocols. They're now focusing on combining the nanoparticle system with other standard TB antibiotics, since combination therapy remains essential for curing tuberculosis.

For the 10 million people diagnosed with TB each year, this innovation could transform treatment from a grueling daily ordeal into a manageable weekly routine. Better adherence means more people cured and fewer drug-resistant infections spreading worldwide.